Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.47 |
| ▸ | CMA1 | P23946 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 6/20 | 0.46 |
| ▸ | DRD2 | P14416 | 6/20 | 0.46 |
| ▸ | HTR2A | P28223 | 6/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | PGR | P06401 | 2/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.46 |
| ▸ | HTR3B | O95264 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | GOT1 | P17174 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30204354 | 1.00 | AHR (0.47) | AHRCMA1HTR1ADRD2HTR2A | |
| SCHEMBL6184160 | 0.91 | AHR (0.45) | AHRCMA1HTR1ADRD2HTR2A | |
| SCHEMBL5791985 | 0.91 | AHR (0.45) | AHRCMA1HTR1ADRD2HTR2A | |
| SCHEMBL7944161 | 0.86 | AHR (0.46) | AHRCMA1HTR1ADRD2HTR2A | |
| SCHEMBL30204500 | 0.86 | AHR (0.46) | AHRCMA1HTR1ADRD2HTR2A | |
| SCHEMBL8230949 | 0.86 | AHR (0.46) | AHRCMA1HTR1ADRD2HTR2A | |
| SCHEMBL13799364 | 0.86 | AHR (0.46) | AHRCMA1HTR1ADRD2HTR2A | |
| SCHEMBL931526 | 0.86 | AHR (0.46) | AHRCMA1HTR1ADRD2HTR2A | |
| SCHEMBL19751042 | 0.83 | AHR (0.50) | AHRCMA1HTR1ADRD2HTR2A | |
| SCHEMBL623837 | 0.83 | HTR1A (0.46) | AHRCMA1HTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117517501-A | Ziprasidone hydrochloride, synthesis intermediate thereof and liquid chromatography detection method of impurities | 湖南省湘中制药有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-112961150-A | Impurities in ziprasidone hydrochloride and preparation method thereof | 海南鑫开源医药科技有限公司 | 2021-06-15 | — | — | CN | claimed |
| CN-112724066-A | Dihalogen impurity in ziprasidone hydrochloride intermediate and preparation method thereof | 海南鑫开源医药科技有限公司 | 2021-04-30 | — | — | CN | claimed |
| EP-2046786-B1 | POLYMORPHIC FORMS OF ZIPRASIDONE SULFATES | KRKA (SI) | 2017-12-27 | — | — | EP | claimed |
| US-7777037-B2 | Ziprasidone process | DR. REDDY'S LABORATORIES LIMITED (IN) | 2010-08-17 | — | — | US | claimed |
| WO-2010073255-A1 | PROCESS FOR PREPARING ZIPRASIDONE | CADILA HEALTHCARE LIMITED (IN) | 2010-07-01 | — | — | WO | claimed |
| CN-101735212-A | Controlled synthesis of ziprasidone and compositions thereof | PFIZER PROD INC | 2010-06-16 | — | — | CN | claimed |
| US-20090137605-A1 | POLYMORPHIC FORMS OF ZIPRASIDONEAND ITS HYDROCHLORIDE SALT AND PROCESS FOR PREPARATION THEREOF | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-05-28 | — | — | US | claimed |
| EP-2046786-A2 | POLYMORPHIC FORMS OF ZIPRASIDONE SULFATES | KRKA (SI) | 2009-04-15 | — | — | EP | claimed |
| US-20090047354-A1 | PROCESS FOR THE PREPARATION OF 5-(2-(4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL) ETHYL)-6-CHLORO-1, 3-DIHYDRO-2H-INDOL-2-ONE HYDROCHLORIDE (ZIPRASIDONE HYDROCHLORIDE) AND ITS INTERMEDIATE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-02-19 | — | — | US | claimed |
| EP-1476162-B1 | CONTROLLED SYNTHESIS OF ZIPRASIDONE | PFIZER PROD INC (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006047893-A1 | PROCESS FOR THE PREPARATION OF ZIPRASIDONE (5-[2-[4-(1,2-BENZISOTHIAZOL-3-Y1)-1-PIPERAZINY1]ETHY1]-6-CHLORO-1,3-DIHYDRO-2H-INDOL-2-ONE) | APOTEX PHARMACHEM INC. (CA) | 2006-05-11 | — | — | WO | claimed |
| US-20060089502-A1 | Ziprasidone process | DR. REDDY'S LABORATORIES, INC. | 2006-04-27 | — | — | US | claimed |
| CN-1635892-A | Controlled synthesis of ziprasidone and compositions thereof | PFIZER (US) | 2005-07-06 | — | — | CN | claimed |
| US-20050049295-A1 | Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate | DR. REDDY'S LABORATORIES LIMITED | 2005-03-03 | — | — | US | claimed |
| EP-1476162-A1 | CONTROLLED SYNTHESIS OF ZIPRASIDONE AND COMPOSITIONS THEREOF | Pfizer Products Inc. (US) | 2004-11-17 | — | — | EP | claimed |
| US-20040152711-A1 | Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof | DR. REDDY'S LABORATORIES LIMITED | 2004-08-05 | — | — | US | claimed |
| WO-2004050655-A1 | POLYMORPHIC FORMS OF ZIPRASIDONE AND ITS HYDROCHLORIDE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2004-06-17 | — | — | WO | claimed |
| US-20040048876-A1 | Ziprasidone composition and synthetic controls | PFIZER INC. | 2004-03-11 | — | — | US | claimed |
| WO-2003070246-A1 | CONTROLLED SYNTHESIS OF ZIPRASIDONE AND COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2003-08-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049295-A1 | Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate | OPRK1, TPH1, TPH2 | AHR 699/4885CMA1 116/4885HTR1A 5/4885 |
| US-20060089502-A1 | Ziprasidone process | HAMP, ZNF277, SLC39A3 | AHR 1610/4885CMA1 331/4885HTR1A 52/4885 |
| US-20040048876-A1 | Ziprasidone composition and synthetic controls | SLC39A3, HAMP, NISCH | AHR 1643/4885CMA1 572/4885HTR1A 138/4885 |
| US-20040152711-A1 | Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof | SLC6A3, SLC39A3, ZNF277 | AHR 3437/4885CMA1 413/4885HTR1A 709/4885 |
| US-20090137605-A1 | POLYMORPHIC FORMS OF ZIPRASIDONEAND ITS HYDROCHLORIDE SALT AND PROCESS FOR PREPARATION THEREOF | SLC6A3, SLC39A3, ZNF277 | AHR 3328/4885CMA1 537/4885HTR1A 535/4885 |
| US-20090047354-A1 | PROCESS FOR THE PREPARATION OF 5-(2-(4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL) ETHYL)-6-CHLORO-1, 3-DIHYDRO-2H-INDOL-2-ONE HYDROCHLORIDE (ZIPRASIDONE HYDROCHLORIDE) AND ITS INTERMEDIATE | OPRK1, OPRD1, TPH1 | AHR 711/4885CMA1 125/4885HTR1A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.